A new study examining decentralized clinical trials (DCTs) found that easing patient access can increase operational complexity for sponsors and CROs. Researchers reported higher staff workload, more difficult sample management due to supply chains and temperature control, and added regulatory variability across jurisdictions. The analysis also pointed to platform fragmentation and gaps in digital literacy as contributors to real-world execution risk, including the stress of remote monitoring and potential workflow disruption if digital devices fail. The findings add to the internal debate over how to operationalize DCTs at scale: patient convenience may come with added burdens on trial teams, making device, logistics, and compliance planning central to feasibility.